VANGL1 and glioma: KITENIN expression was found to be higher in tumor samples from patients with more invasive and malignant gliomas (WHO grades III and IV) than in samples from patients with lower grade gliomas (WHO grades I and II) and normal tissue, similar to findings in other systemic cancers [20, 32, 33].